What is Open Innovation in pharmaceutical R&D? 18/07/2024 Healthcare Access to innovation Drug discovery Innovative drugs The core idea of Open innovation is that companies leverage the ideas and resources of external actors such as customers... Partners - GENESIS Biomed
The European authority HERA visits HIPRA for its productive capacity in the face of future... 27/06/2024 Healthcare Access to innovation Drug discovery Industrial biotechnology The top leadership team from HERA (Health Emergency Preparedness and Response), the European Commission's authority for... Partners - HIPRA HUMAN HEALTH S.L.U.
Juan Basterra (Mikrobiomik) | "In the last 10 years, decisive steps have been taken to und... 27/06/2024 Healthcare Drug discovery Innovative drugs Mikrobiomik is working to become the first company globally to market the first biological drug based on gut microbiota... AseBio - Mikrobiomik
Alira Health Publishes a White Paper on the Impact of New European Union Regulations on Ad... 21/06/2024 Healthcare Access to innovation Drug discovery It provides an overview of the key changes that will impact access to innovative medicines and advanced therapies in the... Partners
ORYZON presents preliminary data from ongoing Phase Ib FRIDA trial with iadademstat plus ... 14/06/2024 Healthcare Access to innovation Drug discovery Rare diseases Data from the first two cohorts demonstrated that combination of iadademstat plus gilteritinib was safe and showed... Partners - Oryzon Genomics
Rafael Simó: "We should talk about "obesities" instead of "obesity" because more and more... 06/06/2024 Healthcare Access to innovation Drug discovery Geneis Biomed interviews Dr. Rafael Simón, head of the Endocrinology and Nutrition Department at Vall d'Hebron... Partners - GENESIS Biomed
Oryzon selected as Associated Partner in the first Important Project of Common European In... 29/05/2024 Healthcare Access to innovation Drug discovery Rare diseases Innovative drugs Personalized medicine Financing Commission has approved up to €1 billion of State aid by six Member States: Belgium, France, Hungary, Italy, Slovakia... Partners - Oryzon Genomics
Key Considerations for Cell and Gene Therapy Commercialization in Non-Orphan Indications 29/05/2024 Healthcare Access to innovation Drug discovery There are two important challenges for companies aiming to develop CGTs in mainstream indications. Partners
Atlas Molecular Pharma successfully completes phase one in humans of its treatment for Con... 28/05/2024 Healthcare Access to innovation Drug discovery Rare diseases Innovative drugs Personalized medicine The final results of ATL-001, the biotech company's lead candidate, have shown that it is able to stabilize UROIIIS and... Partners - Inveready
Launch of Immunostep's New Reagent for CAR T Cell Detection 27/05/2024 Healthcare Access to innovation Drug discovery Immunostep introduces an innovative reagent for CAR T cell detection, enhancing precision and efficiency in cancer... Partners
